Information you can trust.

SCAN 2025 – NET patient survey (New Zealand)

The New Zealand reading of the global SCAN 2025 survey of neuroendocrine cancer patients and clinicians – how our care compares with the world.

Merkel Cell Carcinoma – Ben Lawrence

Merkel Cell Carcinoma, a rare neuroendocrine cancer of the skin, explained for patients and whānau.

SIRT – Dr Sofiullah Abubakar and Dr Michael Sunderland

A Zoom session on selective internal radiation therapy (SIRT), for anyone who could not join on the night.

Understanding neuroendocrine care in New Zealand – Ben Lawrence

How neuroendocrine cancer care is organised in New Zealand, and what that means for the people in it.

Patient Guide

This booklet has been developed to provide information about neuroendocrine tumours (NETs) for patients and their families.

MEN1 syndrome (Multiple Endocrine Neoplasia type 1)

MEN1 is a rare inherited condition that causes tumours in the endocrine glands – the parathyroids, pituitary and pancreas. What it is, what causes it, and how it is diagnosed.

Neuroendocrine carcinomas – Dr John Mak

A recorded education session with Dr John Mak on neuroendocrine carcinomas (NECs) – aggressive, fast-growing cancers that behave quite differently from the NETs we usually focus on.

Types of scans for NET Cancers

There are various types of scans that may or may not be suitable for your type of NETs. Here is a summary of some scans you might encounter.

Grades of Neuroendocrine (NET) Cancers

What G1, G2 and G3 mean for a neuroendocrine cancer diagnosis – plain-language explanation of grade, Ki-67, and how they shape treatment options.

Types of Neuroendocrine Tumours

Neuroendocrine Tumours (NETs) is an umbrella name for a number of different types of tumours, which can arise in different areas of the body. It can be…

PRRT patient guide

Patient guide to peptide receptor radionuclide therapy (PRRT) for NETs.

Treatments for NETs

Treatments for neuroendocrine cancers vary from person to person and may be one or more of the options listed below.

Glossary

Plain-language definitions of common neuroendocrine tumour (NET) terms – for patients, whānau, and care partners. Updated as new treatments and tests come into NZ practice.

A second PRRT in the FDA pipeline: 177Lu-edotreotide decision due August 2026

The FDA is expected to decide on ITM-11 (177Lu-edotreotide) for GEP-NETs by 28 August 2026, based on the Phase 3 COMPETE trial results.

Early signals from alpha-emitter PRRT in SSTR2-positive NETs

A first-in-human trial of [212Pb]VMT-α-NET, a targeted alpha-particle therapy for SSTR2-positive NETs, has reported early activity at ASCO GI 2026.

Understanding Neuroendocrine

Neuroendocrine tumours (NETs) is the umbrella term for a group of unusual, often slow-growing cancers.

Surgery for NETs – Professor Jonathan Koea

A recorded Zoom-In session with Professor Jonathan Koea on surgery for neuroendocrine tumours.

MIBG Therapy for NETs – Dr Rachelle Steyn

A recorded Zoom-In session with Dr Rachelle Steyn on MIBG therapy for neuroendocrine tumours.

Targeted Alpha Therapies and NETs – Dr Andrew Henderson

A recorded Zoom-In session with Dr Andrew Henderson on targeted alpha therapies for neuroendocrine tumours.

Radiology in NETs – Dr Jane Reeve

A recorded Zoom-In session with Dr Jane Reeve on imaging and radiology for neuroendocrine tumours.

Cabozantinib approved by the FDA for previously treated advanced NETs

The CABINET trial led the FDA to approve cabozantinib in March 2025 for adults and adolescents with previously treated advanced pancreatic and extra-pancreatic NETs.

NETTER-2 supports PRRT as a first-line option in advanced GEP-NETs

The Phase 3 NETTER-2 trial showed Lutathera plus octreotide nearly tripled progression-free survival when used as first-line therapy in grade 2/3 GEP-NETs.

Paragangliomas and Pheochromocytomas - July 2024

When NET cancers run in families: inherited syndromes

Most neuroendocrine cancers aren't inherited, but a small number are linked to hereditary syndromes like MEN1, MEN2 and VHL. Here's what to know.